Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Efficacy of antibody-drug conjugate brentuximab vedotin in treating Hodgkin's lymphoma.

Viviani S, Guidetti A.

Expert Opin Biol Ther. 2018 Aug;18(8):841-849. doi: 10.1080/14712598.2018.1499723. Epub 2018 Jul 23.

PMID:
29999431
2.

A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy.

Trnĕný M, Verhoef G, Dyer MJ, Ben Yehuda D, Patti C, Canales M, Lopez A, Awan FT, Montgomery PG, Janikova A, Barbui AM, Sulek K, Terol MJ, Radford J, Guidetti A, Di Nicola M, Siraudin L, Hatteville L, Schwab S, Oprea C, Gianni AM.

Haematologica. 2018 Aug;103(8):1351-1358. doi: 10.3324/haematol.2017.168401. Epub 2018 May 10.

3.

Allogeneic transplantation for relapsed and refractory Hodgkin lymphoma: long-term outcomes and graft-versus-host disease-free/relapse-free survival.

Spina F, Radice T, De Philippis C, Soldarini M, Di Chio MC, Dodero A, Guidetti A, Viviani S, Corradini P.

Leuk Lymphoma. 2018 May 1:1-9. doi: 10.1080/10428194.2018.1459607. [Epub ahead of print]

PMID:
29716416
4.

Early reduction of serum TARC levels may predict for success of ABVD as frontline treatment in patients with Hodgkin Lymphoma.

Guidetti A, Mazzocchi A, Miceli R, Paterno' E, Taverna F, Spina F, Crippa F, Farina L, Corradini P, Gianni AM, Viviani S.

Leuk Res. 2017 Nov;62:91-97. doi: 10.1016/j.leukres.2017.09.018. Epub 2017 Sep 25.

PMID:
28992524
5.

High-dose chemotherapy followed by autologous transplantation may overcome the poor prognosis of diffuse large B-cell lymphoma patients with MYC/BCL2 co-expression.

Maura F, Guidetti A, Pellegrinelli A, Dodero A, Pennisi M, Caprioli C, Testi A, Farina L, Bolli N, Devizzi LF, Cabras A, Corradini P.

Blood Cancer J. 2017 Mar 17;7(3):e544. doi: 10.1038/bcj.2017.25. No abstract available.

6.

High-dose chemotherapy followed by autologous transplantation may overcome the poor prognosis of diffuse large B-cell lymphoma patients with MYC/BCL2 co-expression.

Maura F, Guidetti A, Pellegrinelli A, Dodero A, Pennisi M, Caprioli C, Testi A, Farina L, Bolli N, Devizzi LF, Cabras A, Corradini P.

Blood Cancer J. 2016 Nov 4;6(11):e491. doi: 10.1038/bcj.2016.99. No abstract available. Erratum in: Blood Cancer J. 2017 Mar 17;7(3):e544.

7.

Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseases.

Guidetti A, Carlo-Stella C, Locatelli SL, Malorni W, Mortarini R, Viviani S, Russo D, Marchianò A, Sorasio R, Dodero A, Farina L, Giordano L, Di Nicola M, Anichini A, Corradini P, Gianni AM.

Clin Cancer Res. 2014 Nov 15;20(22):5641-51. doi: 10.1158/1078-0432.CCR-14-0770. Epub 2014 Sep 19.

8.

Stroke/thromboembolism and intracranial hemorrhage in a real-world atrial fibrillation population: the Complications of Atrial Fibrillation in the Bologna Area (CAFBO) study.

Palareti G, Salomone L, Cavazza M, Guidi M, Muscari A, Boriani G, Di Micoli A, Guizzardi G, Procaccianti G, Guidetti A, Binetti N, Malservisi S, Masina M, Viola A, Bua V, Ongari M, Diaspri G, Lip GYH.

Chest. 2014 Oct;146(4):1073-1080. doi: 10.1378/chest.13-2443.

PMID:
24810397
9.

Results of a randomized trial comparing high-dose chemotherapy plus Auto-SCT and R-FC in CLL at diagnosis.

Magni M, Di Nicola M, Patti C, Scimè R, Mulè A, Rambaldi A, Intermesoli T, Viero P, Tarella C, Gueli A, Bergui L, Trentin L, Barzan A, Benedetti F, Ambrosetti A, Di Raimondo F, Chiarenza A, Parvis G, Billio A, Attolico I, Olivieri A, Montanari M, Carlo-Stella C, Matteucci P, Devizzi L, Guidetti A, Viviani S, Valagussa P, Gianni AM.

Bone Marrow Transplant. 2014 Apr;49(4):485-91. doi: 10.1038/bmt.2013.214. Epub 2014 Jan 20.

PMID:
24442244
10.

Plerixafor 'on demand': results of a strategy based on peripheral blood CD34+ cells in lymphoma patients at first or subsequent mobilization with chemotherapy+G-CSF.

Farina L, Guidetti A, Spina F, Roncari L, Longoni P, Ravagnani F, Carlo-Stella C, Corradini P.

Bone Marrow Transplant. 2014 Mar;49(3):453-5. doi: 10.1038/bmt.2013.193. Epub 2013 Dec 9. No abstract available.

PMID:
24317127
11.

Long-Term Results of Autologous Hematopoietic Stem-Cell Transplantation After High-Dose 90Y-Ibritumomab Tiuxetan for Patients With Poor-Risk Non-Hodgkin Lymphoma Not Eligible for High-Dose BEAM.

Devizzi L, Guidetti A, Seregni E, Passera R, Maccauro M, Magni M, Testi A, Di Nicola M, Tarella C, Matteucci P, Viviani S, Ruella M, Carlo-Stella C, Chiesa C, Cox MC, Bombardieri E, Gianni AM.

J Clin Oncol. 2013 Aug 10;31(23):2974-6. doi: 10.1200/JCO.2013.50.2922. Epub 2013 Jul 15. No abstract available.

12.

Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte-colony-stimulating factor: an algorithm for the pre-emptive use of plerixafor.

Farina L, Spina F, Guidetti A, Longoni P, Ravagnani F, Dodero A, Montefusco V, Carlo-Stella C, Corradini P.

Leuk Lymphoma. 2014 Feb;55(2):331-6. doi: 10.3109/10428194.2013.802783. Epub 2013 Jun 14.

PMID:
23656194
13.

Sorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells.

Carlo-Stella C, Locatelli SL, Giacomini A, Cleris L, Saba E, Righi M, Guidetti A, Gianni AM.

PLoS One. 2013 Apr 19;8(4):e61603. doi: 10.1371/journal.pone.0061603. Print 2013.

14.

Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts.

Locatelli SL, Giacomini A, Guidetti A, Cleris L, Mortarini R, Anichini A, Gianni AM, Carlo-Stella C.

Leukemia. 2013 Aug;27(8):1677-87. doi: 10.1038/leu.2013.28. Epub 2013 Jan 30.

PMID:
23360848
15.

Detection of minimal residual disease in hematopoietic progenitor cell harvests: lack of predictive value of peripheral blood and bone marrow analysis in mantle cell and indolent lymphoma.

Magni M, Di Nicola M, Carlo-Stella C, Matteucci P, Devizzi L, Guidetti A, Ravagnani F, Gianni AM.

Am J Blood Res. 2012;2(2):105-12. Epub 2012 Apr 15.

16.

Phase II study of sorafenib in patients with relapsed or refractory lymphoma.

Guidetti A, Carlo-Stella C, Locatelli SL, Malorni W, Pierdominici M, Barbati C, Mortarini R, Devizzi L, Matteucci P, Marchianò A, Lanocita R, Farina L, Dodero A, Tarella C, Di Nicola M, Corradini P, Anichini A, Gianni AM.

Br J Haematol. 2012 Jul;158(1):108-19. doi: 10.1111/j.1365-2141.2012.09139.x. Epub 2012 May 10.

PMID:
22571717
17.

Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia.

Guidetti A, Carlo-Stella C, Ruella M, Miceli R, Devizzi L, Locatelli SL, Giacomini A, Testi A, Buttiglieri S, Risso A, Mariani L, Di Nicola M, Passera R, Tarella C, Gianni AM.

Cancer. 2011 Nov 15;117(22):5074-84. doi: 10.1002/cncr.26182. Epub 2011 May 12.

18.

Efficacy and safety of high-dose chemotherapy with in vivo purged auto-SCT in relapsed follicular lymphoma: long-term follow-up.

Magni M, Di Nicola M, Carlo-Stella C, Devizzi L, Guidetti A, Matteucci P, Gianni AM.

Bone Marrow Transplant. 2010 Jun;45(6):1119-20. doi: 10.1038/bmt.2009.294. Epub 2009 Oct 12. No abstract available.

PMID:
19820728
19.

Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin's lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin).

Chiesa C, Botta F, Coliva A, Maccauro M, Devizzi L, Guidetti A, Carlo-Stella C, Seregni E, Gianni MA, Bombardieri E.

Eur J Nucl Med Mol Imaging. 2009 Nov;36(11):1745-57. doi: 10.1007/s00259-009-1141-x. Epub 2009 May 20.

PMID:
19455328
20.

Radioimmunotherapy and secondary leukemia: a case report.

Magni M, Di Nicola M, Testi A, Cabras A, Devizzi L, Guidetti A, Matteucci P, Viviani S, Bonfante V, Carniti C, Ricca I, Carbone A, Carlo-Stella C, Gianni AM.

Leuk Res. 2010 Jan;34(1):e1-4. doi: 10.1016/j.leukres.2009.04.028. Epub 2009 May 15.

PMID:
19446876
21.

High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantation.

Devizzi L, Guidetti A, Tarella C, Magni M, Matteucci P, Seregni E, Chiesa C, Bombardieri E, Di Nicola M, Carlo-Stella C, Gianni AM.

J Clin Oncol. 2008 Nov 10;26(32):5175-82. doi: 10.1200/JCO.2008.16.8294. Epub 2008 Oct 14.

PMID:
18854569
22.

Dosimetry in myeloablative (90)Y-labeled ibritumomab tiuxetan therapy: possibility of increasing administered activity on the base of biological effective dose evaluation. Preliminary results.

Chiesa C, Botta F, Di Betta E, Coliva A, Maccauro M, Aliberti G, Bavusi S, Devizzi L, Guidetti A, Seregni E, Gianni AM, Bombardieri E.

Cancer Biother Radiopharm. 2007 Feb;22(1):113-20.

PMID:
17627419
23.

IFN-gamma enhances the antimyeloma activity of the fully human anti-human leukocyte antigen-DR monoclonal antibody 1D09C3.

Carlo-Stella C, Guidetti A, Di Nicola M, Lavazza C, Cleris L, Sia D, Longoni P, Milanesi M, Magni M, Nagy Z, Corradini P, Carbone A, Formelli F, Gianni AM.

Cancer Res. 2007 Apr 1;67(7):3269-75.

24.

Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma.

Ladetto M, Magni M, Pagliano G, De Marco F, Drandi D, Ricca I, Astolfi M, Matteucci P, Guidetti A, Mantoan B, Bodoni CL, Zanni M, Boccadoro M, Gianni AM, Tarella C.

Biol Blood Marrow Transplant. 2006 Dec;12(12):1270-6.

25.

CD52 antigen expressed by malignant plasma cells can be targeted by alemtuzumab in vivo in NOD/SCID mice.

Carlo-Stella C, Guidetti A, Di Nicola M, Longoni P, Cleris L, Lavazza C, Milanesi M, Milani R, Carrabba M, Farina L, Formelli F, Gianni AM, Corradini P.

Exp Hematol. 2006 Jun;34(6):721-7.

PMID:
16728276
26.

Topical prophylaxis of conjunctivitis induced by high-dose cytosine arabinoside.

Matteucci P, Carlo-Stella C, Di Nicola M, Magni M, Guidetti A, Marchesi M, Gianni AM.

Haematologica. 2006 Feb;91(2):255-7.

27.

High response rate and manageable toxicity with an intensive, short-term chemotherapy programme for Burkitt's lymphoma in adults.

Di Nicola M, Carlo-Stella C, Mariotti J, Devizzi L, Massimino M, Cabras A, Magni M, Matteucci P, Guidetti A, Gandola L, Gianni AM.

Br J Haematol. 2004 Sep;126(6):815-20.

PMID:
15352985
28.

Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: a phase I trial in metastatic melanoma.

Di Nicola M, Carlo-Stella C, Mortarini R, Baldassari P, Guidetti A, Gallino GF, Del Vecchio M, Ravagnani F, Magni M, Chaplin P, Cascinelli N, Parmiani G, Gianni AM, Anichini A.

Clin Cancer Res. 2004 Aug 15;10(16):5381-90.

29.

Age- and irradiation-associated loss of bone marrow hematopoietic function in mice is reversed by recombinant human growth hormone.

Carlo-Stella C, Di Nicola M, Milani R, Longoni P, Milanesi M, Bifulco C, Stucchi C, Guidetti A, Cleris L, Formelli F, Garotta G, Gianni AM.

Exp Hematol. 2004 Feb;32(2):171-8.

PMID:
15102478
30.

Use of recombinant human growth hormone (rhGH) plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the mobilization and collection of CD34+ cells in poor mobilizers.

Carlo-Stella C, Di Nicola M, Milani R, Guidetti A, Magni M, Milanesi M, Longoni P, Matteucci P, Formelli F, Ravagnani F, Corradini P, Gianni AM.

Blood. 2004 May 1;103(9):3287-95. Epub 2004 Jan 15.

31.

Mobilization of primitive and committed hematopoietic progenitors in nonhuman primates treated with defibrotide and recombinant human granulocyte colony-stimulating factor.

Carlo-Stella C, Di Nicola M, Longoni P, Milani R, Milanesi M, Guidetti A, Haanstra K, Jonker M, Cleris L, Magni M, Formelli F, Gianni AM.

Exp Hematol. 2004 Jan;32(1):68-75.

PMID:
14725903
32.

Clinical protocol. Immunization of patients with malignant melanoma with autologous CD34(+) cell-derived dendritic cells transduced ex vivo with a recombinant replication-deficient vaccinia vector encoding the human tyrosinase gene: a phase I trial.

Di Nicola M, Carlo-Stella C, Anichini A, Mortarini R, Guidetti A, Tragni G, Gallino F, Del Vecchio M, Ravagnani F, Morelli D, Chaplin P, Arndtz N, Sutter G, Drexler I, Parmiani G, Cascinelli N, Gianni AM.

Hum Gene Ther. 2003 Sep 20;14(14):1347-60. No abstract available.

PMID:
14503969
33.

Cytokine secretion associated with the clearance of apoptotic bodies in renal cell carcinoma patients.

Bondanza A, Rovere P, Borri A, Caremoli ER, Guidetti A, Citterio G, Consogno G, Zimmermann VS, Rugarli C, Manfredi AA.

Int J Cancer. 2001 Mar 1;91(5):713-7.

34.

[External radiotherapy in early stage squamous cell carcinoma of the supraglottic larynx. Report of 28 cases].

Caliceti U, Frezza G, Galuppi A, Guidetti A, Pasquini E, Sorrenti G, Cavicchi O, Rinaldi Ceroni A.

Acta Otorhinolaryngol Ital. 1996 Feb;16(1):35-9. Review. Italian.

PMID:
8984838
35.

[Radiotherapy of stage T1 carcinoma of the glottis. Analysis of prognostic factors in 154 patients].

Frezza G, Bunkheila F, Caliceti U, Gabbani M, Galuppi A, Guidetti A, Silvano M, Sorrenti G, Babini L.

Radiol Med. 1995 Jun;89(6):850-4. Italian.

PMID:
7644741
36.

[Poliomyelitis surveillance: seroepidemiologic study on a Piedmont population sample].

Maiello A, Ossola O, Guidetti A, Zotti C, Moiraghi Ruggenini A.

Ann Ist Super Sanita. 1995;31(3):317-22. Italian.

PMID:
8712575
37.

[Incipient carious lesions in patients undergoing fixed orthodontic treatment: a proposed specific prevention plan].

Riccio C, Guidetti AM, Piccirillo P.

Arch Stomatol (Napoli). 1990 Jul-Sep;31(3):499-505. Italian. No abstract available.

PMID:
2097966
38.

Haemoptysis as the sole presenting symptom of dissection of the aorta.

Guidetti AS, Pik A, Peer A, Shikiar S, Ben-Yaakov D.

Thorax. 1989 May;44(5):444-5.

39.

[Cavity preparation for posterior composites].

Riccio C, Guidetti AM, Piccirillo P.

Attual Dent. 1989 Mar 19;5(11):18-23. Italian. No abstract available.

PMID:
2635026
40.

[Change in position of the lingual bar].

Buonaiuto C, Riccio C, Guidetti AM.

Arch Stomatol (Napoli). 1983 Jan-Mar;24(1):101-5. Italian. No abstract available.

PMID:
6367702
41.

[Space maintenance in clinical practice].

Riccio C, Guidetti AM, Parlato M.

Arch Stomatol (Napoli). 1982 Jan-Mar;23(1):181-8. Italian. No abstract available.

PMID:
6963140
42.

[Overview on the power of the oral cavity defenses].

Riccio C, Guidetti AM, Parlato M.

Arch Stomatol (Napoli). 1981 Jan-Mar;22(1):69-82. Italian. No abstract available.

PMID:
6960833
43.

[Clinical findings on the use of milk in liquid form].

Loidice G, Guidetti A, Fortuna C, Paini A, Ria N, D'Elia R, Fornaro C.

Minerva Pediatr. 1976 Aug 18;28(26):1639-42. Italian. No abstract available.

PMID:
1037012
44.

[Clinical considerations on 2 cases of congenital malformations in children born to mothers with chronic alcoholism. (1. Italian cases)].

Loiodice G, Fortuna G, Guidetti A, Ria N, D'Elia R.

Minerva Pediatr. 1975 Nov 3;27(34):1891-3. Italian. No abstract available.

PMID:
1228444
45.

[K40 in the human body in relation to absorbed doses].

Guidetti A, Indelicato S.

Minerva Med. 1970 Feb 21;61(15):689-93. Italian. No abstract available.

PMID:
5417561
46.

[New method of investigation of the biliary trct: perfusional cholangiocholecystography].

Ricci A, Guidetti A.

Nunt Radiol. 1966 Oct;32(10):1047-57. Italian. No abstract available.

PMID:
5996128
47.

[Senna].

LEVI A, GUIDETTI A.

Boll Chim Farm. 1954 Jun;93(6):203-17. Italian. No abstract available.

PMID:
13199092

Supplemental Content

Loading ...
Support Center